Video Experimental Relacionado

Updated: Sep 9, 2025

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Sintilimab más anlotinib en pacientes con sarcoma localmente avanzado o metastásico previamente tratado: un ensayo

Heng Fu¹, Zengjun Liu², Mengyao Liu²

¹Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji Nan, China.

Cancer immunology research

|August 28, 2025

Resumen

Sintilimab más anlotinib se muestra prometedor para los sarcomas avanzados, logrando una tasa de respuesta objetiva del 30, 9%. Las estructuras linfoides terciarias predicen mejores respuestas, lo que indica posibles estrategias de tratamiento personalizadas para pacientes con sarcoma.

Área de la Ciencia:

Oncología médica
La inmunoterapia
Investigación del sarcoma

Sus antecedentes:

Los sarcomas avanzados presentan opciones terapéuticas limitadas después del tratamiento estándar.
La investigación de nuevas terapias combinadas es crucial para mejorar los resultados de los pacientes.

Objetivo del estudio:

Evaluar la eficacia y seguridad de sintilimab en combinación con anlotinib en pacientes con sarcomas avanzados.
Explorar el papel predictivo de las estructuras linfoides terciarias (TLS) en la respuesta al tratamiento.

Principales métodos:

Un ensayo clínico en el que participaron pacientes de entre 18 y 75 años con sarcomas avanzados que habían recibido tratamiento sistémico previo.
Los pacientes recibieron sintilimab (200 mg) y anlotinib (8, 10 o 12 mg) cada 3 semanas.
Se evaluó la tasa de respuesta objetiva (ORR), la supervivencia libre de progresión (PFS), la supervivencia global (OS) y los eventos adversos (EA).

Principales resultados:

El ORR fue del 30,9% y la tasa de control de la enfermedad (DCR) fue del 76,2%.
La SFP mediana fue de 5,0 meses; no se alcanzó la OS mediana.
Se observó una mayor ORR en los pacientes con TLS positivo (71,4%) en comparación con los pacientes con TLS negativo (25,0%).

Conclusiones:

Sintilimab más anlotinib demuestra una actividad antitumoral significativa y una toxicidad manejable en sarcomas avanzados.
El estado de TLS es un potencial biomarcador predictivo de la respuesta a este tratamiento combinado.

Más Videos Relacionados

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Videos de Conceptos Relacionados

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...